What is MYELOMA?
¡ Multiple myeloma, also called simply “myeloma,” is a cancer of the bone marrow plasma cells. Myeloma is “multiple” because there may be multiple areas in the bone marrow where it grows.
¡ Myeloma is treatable and many patients live long and productive lives after being diagnosed.
¡ The National Cancer Institute SEER Program estimates that 36,000 new cases of myeloma will be diagnosed in the U.S. in 2026.
¡ In 70% of patients, the most common symptoms of myeloma are back or bone pain, unexplained fatigue, and recurrent or persistent infections.
¡ Men are more likely than women to develop myeloma. It is most frequently diagnosed in individuals who are 65–74 years old, but it is now also being diagnosed in people younger than 50.
¡ Myeloma is the most common blood cancer in patients of African descent, who have twice the risk of developing myeloma when compared to White patients. Visit mpower.myeloma.org.
Have questions about myeloma?
The IMF InfoLine responds to your myeloma-related questions in a compassionate and caring manner. To receive the most up-to-date information, call 1.818.487.7455 or email InfoLine@myeloma.org, or visit mmsm.link/infoline to schedule a time to talk with an IMF InfoLine Coordinator.
Want answers and don’t want to wait? Ask Myelo®, your AI assistant at myeloma.org. Myelo is designed to support you in your life with myeloma and to help you find the right resources.
Founded in 1990, the IMF is the world’s leading organization dedicated to multiple myeloma.
The International Myeloma Foundation (IMF) is steadfast in its mission: Accelerating the prevention and cure of myeloma and improving the quality of life for patients and families.
The IMF combines world-class research, trusted education, global advocacy, and direct support.
The IMF International Myeloma Working Group® (IMWG®) is a cornerstone of this work. The IMWG is comprised of more than 350 renowned researchers and clinicians who establish the guidelines that shape how myeloma is diagnosed, treated, and managed worldwide.
The IMF ensures that scientific advances translate into better patient care and outcomes.
Through the IMF InfoLine, educational programs, a global network of support groups, the 24/7 generative-AI myeloma assistant Myelo®, and our advocacy for healthcare access, the IMF helps people living with myeloma and their care partners navigate diagnosis and survivorship.
Follow the IMF on: